Menu
Search
|

Menu

Close
X

ZIOPHARM Oncology Inc ZIOP.OQ (NASDAQ Stock Exchange Capital Market)

4.73 USD
-0.01 (-0.21%)
As of Sep 13
Previous Close 4.74
Open 4.83
Volume 318,582
3m Avg Volume 504,579
Today’s High 4.85
Today’s Low 4.65
52 Week High 7.25
52 Week Low 1.56
Shares Outstanding (mil) 162.39
Market Capitalization (mil) 972.74
Forward P/E 6.36
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
6
FY16
7
EPS (USD)
FY19
-0.084
FY18
0.875
FY17
-0.536
FY16
-1.322
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
6.36
33.85
Price to Sales (TTM)
vs sector
--
7.90
Price to Book (MRQ)
vs sector
13.10
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-66.24
12.69
Return on Equity (TTM)
vs sector
--
17.13

EXECUTIVE LEADERSHIP

Scott Tarriff
Chairman, Independent Director, Since 2019
Salary: --
Bonus: --
David Mauney
President, Since 2018
Salary: $400,000.00
Bonus: $197,000.00
Laurence Cooper
Chief Executive Officer, Director, Since 2018
Salary: $500,000.00
Bonus: $1,000,000.00
Satyavrat Shukla
Chief Financial Officer, Executive Vice President, Since 2019
Salary: --
Bonus: --
Robert Hadfield
Executive Vice President, Chief Compliance Officer, General Counsel, Secretary, Since 2018
Salary: $254,647.00
Bonus: $113,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

One First Avenue Parris Building
, Navy Yard Plaza
BOSTON   MA   02129

Phone: +1617.2591970

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

SPONSORED STORIES